Can-fite Biopharma Ltd. · TASE:CANF
Can-fite Biopharma — Investor Presentation (January 2016)
21 slides from Can-fite Biopharma's investor presentation, Jan 11, 2016
Slide 1: Can-Fite Presentation – January 2016
Can - Fite Presentation – January 2016
Slide 2: Forward Looking Statement
This presentation contains forward - looking statements, about Can - Fite’s expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects . In addition, from time to time, Can - Fite o
Slide 3: Company Profile
3 Company Profile Operations Financial Summary Proprietary Core Technology • Headquarters & Discovery Labs – Petach - Tikva , Israel • Drug Development & Clinical Operations – Boston, USA • Advanced clinical stage drug development company with a compelling platform technology • Several small molecul
Slide 4: Investment Highlights
Investment Highlights Innovative Technology for the Treatment of Inflammation & Cancer • Selective therapeutic target , highly expressed on pathological but not normal body cells • Strong intellectual property protection (13 patent families) • Advanced clinical studies - Phase II and Phase III Small
Slide 5: Corporate Partnerships
Corporate Partnerships Regional out - licensing deals - ~$ 10 million received to date [Traded on South Korean Stock Exchange (Ticker : A 009290 )] • Exclusive regional license to develop and commercialize CF101 for the treatment of rheumatoid arthritis in Korea • Up to $1.5 M in upfront and milesto
Slide 6: From Concept to Technology Company
From Concept to Technology 6 Company platform technology mimics natural body mechanism to combat cancer and inflammation
Slide 7: Platform Technology: A3 Adenosine Receptor
Therapeutic Target • A 3 adenosine receptor (A 3 AR ) • Highly expressed in inflammatory and cancer cells Drug product • Small molecules • Orally bioavailable drugs Therapeutic Effect • Anti - inflammatory and anti - cancer effects in Phase II studies; Excellent safety profile A 3 AR is utilized as
Slide 8: Drug Development Pipeline
Drug Development Pipeline 8 Operated by our subsidiary OphthaliX (OTCQB: OPLI) In preparation EMA Submission On - going Enrollment completed On - going In preparation
Slide 9: CF101 – Anti-Inflammatory Effect
CF101 – Anti - Inflammatory Effect • Highly Selective A 3 AR Agonist • Nucleoside derivative • Molecular weight - 510.29 • Water insoluble • Orally bioavailable • Half life time in blood – 8 - 9 hours • Is not metabolized in the body; secreted unchanged Properties Proof of concept in pre - clinical
Slide 10: Rheumatoid Arthritis – Positive Data from Phase II Study
Phase IIb study, Placebo controlled; 79 patients Rheumatoid Arthritis - Positive Data from Phase II Study 10 * *MTX, Biological Drugs *MTX, Biological Drugs 1 mg
Slide 11: Rheumatoid Arthritis – Phase III Study
Rheumatoid Arthritis – Phase III Study 11 *MTX, Biological Drugs *MTX, Biological Drugs Phase III - Study Protocol • A Phase III trial to evaluate the efficacy and safety of CF101 when a dded to conventional t herapy in the treatment of rheumatoid a rthritis • 3 arms: 1 mg & 2 mg of CF101 and placeb
Slide 12: CF101 – Psoriasis
CF101 - Psoriasis • Double - blind, placebo - controlled study to test efficacy of CF101 in 320 patients with moderate - to - severe plaque psoriasis • 3 arms: 1 mg & 2 mg of CF101 and placebo o All patients receiving placebo were switched to either 1 mg or 2 mg CF101 after 12 weeks • Study duration
Slide 13: Psoriasis – Data from Phase II/III Study
Psoriasis – Data from Phase II/III Study ▪ The study did not achieve the primary endpoint of PASI 75 at 12 weeks ▪ Excellent safety profile in all tested dosages ▪ Positive linear data on Weeks 12 to 32 Significant Linear Effect of CF101 on PASI Scores through 32 Weeks of Treatment 13 63.5 35.3 24.7
Slide 14: CF101 Compares Favorably To Celgene's Otezla
CF101 Compares Favorably To Celgene’s Otezla® 14 • Otezla® efficacy plateaus at 16 weeks (PASI - 75 ≈ 33 %) • CF 101 shows no visible plateau at 32 weeks (PASI - 75 = 35.3 %) ( 2 Different Studies) Otezla® CF101
Slide 15: CF102 – Anti-Cancer
CF102 – Anti - Cancer • Highly Selective A3AR Agonist • Nucleoside derivative • Molecular weight - 544.73 • Water insoluble • Orally bioavailable • Half life time in blood – 12 hours Properties Proof of concept in pre - clinical pharmacology studies: • Hepatocellular Carcinoma • Colon Carcinoma • Pr
Slide 16: Liver Cancer – Positive Data from Phase I/II Study
Liver Cancer – Positive Data from Phase I/II Study • Very favorable safety profile and lack of hepatotoxicity • Prolongation of survival time • Regression of skin tumor metastases • Stable disease (22%) • Proof of concept for A3AR utilization as a biomarker • U.S. FDA Fast Track & Orphan Drug Design
Slide 17: Liver Cancer – Phase II Global Study Ongoing
Phase II - Study Protocol • Second - Line Treatment • Advanced Hepatocellular Carcinoma; Child - Pugh B • 78 patients; • US, Europe and Israel • Primary end point: overall survival Study Status • Regulatory approvals to commence Phase II study were received in the US, Europe and Israel • Patient enr
Slide 18: CF102 for the Treatment of NASH
CF102 for the Treatment of NASH 18 CF102 markedly improved liver function & pathology in NAFLD and NASH CF102 reduces NAFLD Activity Score (NAS ) Significant decrease in steatosis, ballooning and lobular inflammation A decrease in plasma ALT and triglyceride levels Non - alcoholic fatty liver diseas
Slide 19: CF602 – Sexual Dysfunction – A Safe Drug
CF 602 – Sexual Dysfunction – A Safe Drug 19 Properties Cohen et al . Mediators of Inflammation. 2015 • A 3 AR allosteric modulator • Molecular weight – 411.34 • Water insoluble • Orally bioavailable • Belong to the family of imidazoquinoline derivatives Current status • Manufacturing of CF 602 to b
Slide 20: CF602 – Improvement of Erectile Dysfunction
CF602 – Improvement of Erectile Dysfunction Diabetic Rat Model 20 Intra - cavernous pressure (ICP)/ mean arterial pressure (MAP) ratios CF 602 acts as a vaso - relaxant to promote smooth muscle relaxation and penile erection Placebo CF602 Histological evaluation using a Masson Trichrome stain for sm
Slide 21: Spotlight on Month Milestones
Spotlight on 12 Month Milestones CF102 – PRIMARY LIVER CANCER – PHASE I/II 21 *Sources: Visiongain estimates global psoriasis drug market will be $ 9 b by 2018 and the global rheumatoid arthritis drug market will be $ 38 b by 2017 ; Global Industry Analysts estimates the global liver cancer drug mar
Can-Fite BioPharma — Investor Presentation (January 2016) on 6ix